• Merck KGaA will present 25 oncology and rare tumor abstracts at the ESMO Congress, October 23-26, 2026, in Madrid.
• Precemtabart tocentecan’s first median overall survival results in heavily pretreated metastatic colorectal cancer will be presented October 25.
• Updated Phase 1 efficacy and safety findings for the investigational antibody-drug conjugate will support Phase 3 dose selection.
• Pimicotinib presentations on October 26 will cover two-year Phase 3 efficacy, safety and quality-of-life findings in tenosynovial giant cell tumors.
• A Phase 3 analysis scheduled for October 26 supports Ogsiveo dose reduction to maintain tumor control in patients with desmoid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.